Senator Investment Group LP Takes Position in Scholar Rock Holding Corporation $SRRK

Senator Investment Group LP bought a new position in Scholar Rock Holding Corporation (NASDAQ:SRRK) during the second quarter, Holdings Channel reports. The firm bought 205,000 shares of the company’s stock, valued at approximately $11,275,000.

Several other institutional investors also recently bought and sold shares of SRRK. IFP Advisors Inc lifted its holdings in Scholar Rock by 294.1% in the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after acquiring an additional 450 shares during the period. Caitong International Asset Management Co. Ltd purchased a new position in shares of Scholar Rock during the 4th quarter valued at approximately $30,000. Summit Securities Group LLC acquired a new position in shares of Scholar Rock in the 4th quarter valued at $31,000. Allworth Financial LP purchased a new stake in shares of Scholar Rock during the 2nd quarter worth about $35,000. Finally, EverSource Wealth Advisors LLC boosted its position in Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after purchasing an additional 525 shares in the last quarter. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. BMO Capital Markets restated an “outperform” rating and issued a $76.00 price objective on shares of Scholar Rock in a research report on Friday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, June 18th. HC Wainwright reissued a “buy” rating and issued a $65.00 price target on shares of Scholar Rock in a research note on Monday, August 10th. Barclays boosted their price target on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, Wedbush reaffirmed an “outperform” rating and set a $64.00 price objective on shares of Scholar Rock in a report on Friday, August 21st. Four research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $58.77.

Scholar Rock Stock Performance

SRRK opened at $57.80 on Monday. The firm has a market capitalization of $7.04 billion, a price-to-earnings ratio of -16.75 and a beta of 0.69. The company’s 50 day simple moving average is $53.07 and its two-hundred day simple moving average is $48.90. Scholar Rock Holding Corporation has a 1-year low of $27.07 and a 1-year high of $61.76. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.02 and a quick ratio of 7.02.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.84) EPS for the quarter, meeting the consensus estimate of ($0.84). During the same period last year, the firm posted ($0.98) earnings per share. Analysts expect that Scholar Rock Holding Corporation will post -3.23 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jeffrey S. Flier sold 3,053 shares of Scholar Rock stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total transaction of $164,495.64. Following the transaction, the director owned 27,856 shares in the company, valued at $1,500,881.28. The trade was a 9.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Katie Peng sold 5,446 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.88, for a total transaction of $293,430.48. Following the transaction, the director directly owned 34,301 shares in the company, valued at approximately $1,848,137.88. The trade was a 13.70% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 17,149 shares of company stock worth $923,108. 10.30% of the stock is currently owned by company insiders.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).